$Clearside Biomedical (CLSD.US)$
Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Tuesday, 28th January at 7:05 am
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature
CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -
- CLS-AX Targets Flexible Dosing of Biologics with Duration of Tyrosine Kinase Inhibitors -
ALPHARETTA, Ga., ...

$Clearside Biomedical (CLSD.US)$ Reuters· just
Clearside Biomedical Announces Its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Wednesday, 22nd January at 7:05 am
- ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy -
- Continued Global Expansion of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® -
ALPHARETTA, Ga.,...

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Thursday, 19th December at 7:05 am
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the official journal of The Royal Colleg...

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Clearside Biomedical (NASDAQ: CLSD) showcased its suprachoroidal delivery technology and pipeline programs at multiple medical meetings across Asia, Europe, and the United States. The company made a significant impact at the 17th Asia-Pacific Vitreo-Retina Society Congress in Singapore with presentations on ODYSSEY topline resul...

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
Clearside Biomedical (CLSD) announced that its Asia-Pacific partner, Arctic Vision, has signed a commercial collaboration agreement with Santen Pharmaceutical for ARVN001 (branded as XIPERE® in the US) for treating uveitic macular edema in China. ...

$Clearside Biomedical (CLSD.US)$
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
Clearside Biomedical (Nasdaq: CLSD) presented positive data from its ODYSSEY Phase 2b trial for CLS-AX in wet AMD at the 2024 AAO Annual Meeting. The trial demonstrated extended duration and stable vision, with an 84% reduction in injection frequency after the initial dose. Approximately 90% o...